Global benefit-risk evaluation of antidepressant action: Comparison of pooled data for venlafaxine, SSRIs, and placebo

CNS Spectrums

Volumn 7, Issue 12, 2002, Pages 882-888

  Entsuah, Richard ^a,b   Gao, Bo ^b  

^a VILLANOVA UNIVERSITY   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ABDOMINAL PAIN; ANOREXIA; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; FLU LIKE SYNDROME; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NAUSEA; NERVOUSNESS; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; RANDOMIZED CONTROLLED TRIAL; REMISSION; RISK BENEFIT ANALYSIS; SIDE EFFECT; SOMNOLENCE; TREMOR; VERTIGO; XEROSTOMIA;

EID: 0038122961     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900022513     Document Type: Article

References (33)

1. Chuang-Stein C, Mohberg NR, Sinkula MS. Three measures for simultaneously evaluating benefits and risks using categorical data from clinical trials. Stat Med. 1991;10:1349-1359.
2. Muth EA, Haskins JT, Moyer JA, Husbands GEM, Nielsen ST, Sigg EB. Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol. 1986;35:4493-4497.
3. Itudolph RL, Fabre LF, Feighner JP, et al. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry. 1998;59:116-122.
4. Laird LK, Benefield WH Jr. Mood disorders 1: major depressive disorders. In: Young LY, Koda-Kimble MA, eds. Applied Therapeutics: The Clinical Use of Drugs. Vancouver, Wash: Applied Therapeutics, Inc.; 1995;76-1-76-28.
5. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001;178:234-241.
6. Clerc GE, Ruimy P, Verdeau-Paillès J, on behalf of the Venlafaxine French Inpatient Study Group. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol. 1994;9:139-143.
7. Dierick M, Ravizza L, Realini R, Martin A. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuropsychopharmacol Biol Psychiatry. 1996;20:57-71.
8. Rudolph RL, Feiger AD. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord. 1999;56:171-181.
9. Silverstone PH, Ravindran A. For the Venlafaxine XR 360 Study Group. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. J Clin Psychiatry. 1999;60:22-28.
10. Rudolph R, Entsuah R, Aguiar L, Derivan A. Early onset of antidepressant activity of venlafaxine compared with placebo and fluoxetine in outpatients in a double-blind study [abstract]. Eur Neuropsychopharmacol. 1998;8(suppl 2):S142.
11. Salinas E. Once-daily venlafaxine XR vs. paroxetine in outpatients with major depression [abstract]. Eur Neuropsychopharmacol. 1998;8(suppl 2):S197.
12. Hamilton M. A rating seale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
13. American Psychiatric Association. Diagriostic and Statistical Manual of Mental Disorders. 3rd, revised ed. Washington, DC: American Psychiatric Association, 1987.
14. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th, revised ed. Washington DC: American Psychiatric Association; 1994.
15. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
16. National Institute of Mental Health. Clinical Global Impressions. Psychopharmacol Bull. 1985;21:839-843.
17. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry. 1991;48:851-855.
18. American Psychiatric Association. Practice guideline for major depressive disorder in adults. Am J Psychiatry 1993;150(suppl 4):1-26.
19. Clinical Practice Guideline Number 5: Depression in Primary Cure, 2. Treatment of Major Depression. Rockville, Md: Agency for Health Care Policy and Research, US Department of Health and Human Services; 1993, AHCPR publication No. 93-0551.
20. Entsuah AR, Rudolph RL, Hackett D, Miska S. Efficacy of venlafaxine and placebo during long-term treatment of depression: a pooled analysis of relapse rates. Int Clin Psychopharmacol. 1996;11:137-145.
21. Khan A, Upton GV, Rudolph RL, et al. The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. J Clin Psychopharmacol. 1998;18:19-25.
22. Poirier M-F, Boyer P. Venlafaxine and paroxetine in treatment-resistant depression: double-blind, randomised comparison. Br J Psychiatry. 1999;175:12-16.
23. Ballos C, Quiros G, de Flores T, et al. The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder of dysthymia. Int Clin Psychopharmacol. 2000;15:43-48.
24. Diaz-Martinez A, Benassinni O, Ontiveros A, et al. A randomized, open-label comparison of venlafaxine and fluoxetine in depressed outpatients. Clin Ther. 1998;20:467-476.
25. McPaalin GM, Reynolds A, Anderson C, Casoy J. A comparison of once-daily venlafaxine XR and paroxetine in depressed outpatients treated in general practice. Primary Care Psychiatry. 1998;4:127-1,32.
26. Tzanakaki M, Guazzelli M, Nimatoudis I, et al. Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia. Int Clin Psychopharmacol. 2000;15:29-34.
27. Alves C, Cachola I, Brandao J. Efficacy and tolerability of venlafaxine and fluoxetine in outpatients with major depression. Primary Care Psychiatry. 1999;5:57-63.
28. Entsuah R, Chitra R. A benefit-risk analysis of once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Psychopharmacol Bull. 1997;33:671-676.
29. Entsuah R, Gorman JM. Global benefit-risk assessment of antidepressants: venlafaxine XR and fluoxetine. J Psychiatr Res. 2002;36:111-118.
30. Ballenger JC. Clinical guidelines for establishing remission in patients with depression and anxiety. J Clin Psychiatry 1999;60(suppl 22):29-34.
31. Thase ME. Redefining antidepressant efficacy toward long-term recovery. J Clin Psychiatry. 1999;60(suppl 6):15-19.
32. Costa e Silva J. Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression. J Clin Psychiatry. 1998;59:352-357.
33. Corruble E, Guelfi JD. Is there a relationship between clinical efficacy and antidepressant dosage in major depression? Encephale. 1999;25(special issue 2):39-43.